Versant Ventures said Monday it has appointed Dr. Guido Magni, a scientist and biopharmaceutical clinical development expert, as a venture partner.
The Menlo Park-based venture capital firm said the move is expected to further strengthen its investment team and expand its biotechnology footprint in Europe and other countries. Magni plans to invest in innovative startups as part of Versant’s strategy to fund first-in-class health care technologies.
The firm has $1.6 billion in capital under management.
No comments:
Post a Comment